Uncovering the features of Measles-targeting human antibodies elicited by the MMR vaccine
Related Experiment Video
Updated: Jan 16, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Abstract:
Measles virus (MeV), a highly transmissible paramyxovirus, causes disease that can lead to severe complications and death, particularly in babies and young children. Deployment of the durable, highly effective, live-attenuated measles vaccine has saved an estimated 94 million lives in the past 50 years, 1 yet the immunological explanation for this vaccine's unique success and its landscape of antibody recognition remains unclear. Here we report the first panel of human monoclonal antibodies (mAbs) specific for the MeV hemagglutinin (H) and fusion (F) surface proteins, derived from the memory B cells of an MMR vaccinee. From over 100 cloned human mAbs, we mapped four major epitope clusters on H and another five major clusters on F, and structurally characterized 17 representative mAbs including one or more examples of each of the nine epitope clusters on the two surface antigens. We find that antibodies against both H and F can lead to potent virus neutralization and reduction of viral loads in vivo , including one mAb against F that reduces viral loads to below the limit of detection for all animals. High-resolution cryo-EM reveals contact sites of the most protective antibodies against both surface antigens. Discovery, characterization, and in vitro and in vivo success of these fully human mAbs now provide new avenues for prophylactic or therapeutic intervention against this re-emerging virus.
Highlights:
A large panel of Measles-specific monoclonal antibodies was isolated from a human MMR vaccinee, years after vaccination.Structural and biochemical mapping paints a landscape of antibody recognition with nine major competition groups, including four major sites on Hemagglutinin (H) and five on the fusion protein (F). Antibodies against both H and F confer in vitro neutralization and in vivo protection, including, in one case, undetectable viral load after antibody treatment. The most protective H-specific mAbs, 4D08 and 1C08, target the receptor-binding site and the F-proximal outside of the H dimer, and likely function by interfering with receptor binding and H-F interactions, respectively.The most protective F-specific mAbs, 3A12 and 4F09, target the sides and apex of the prefusion F trimer, and likely function by locking F into its pre-fusion state.
Insights
Researchers identified human monoclonal antibodies targeting measles virus surface proteins. These antibodies neutralize the virus and reduce viral loads, offering new therapeutic strategies against measles.
Area of Science:
- Immunology
- Virology
- Structural Biology
Background:
- Measles virus (MeV) is highly contagious, causing severe illness and death, especially in young children.
- The measles vaccine has saved millions of lives, but the precise immunological mechanisms of its success and antibody recognition are not fully understood.
- Understanding antibody responses is crucial for developing new interventions against re-emerging MeV.
Purpose of the Study:
- To discover and characterize human monoclonal antibodies (mAbs) targeting MeV surface proteins (hemagglutinin (H) and fusion (F)).
- To map the epitope landscape of MeV surface proteins recognized by these mAbs.
- To evaluate the in vitro and in vivo efficacy of these mAbs for potential therapeutic applications.
Main Methods:
- Isolation of human mAbs from memory B cells of an MMR vaccinee.
- Epitope mapping to identify antibody binding sites on H and F proteins.
- Structural characterization using cryo-electron microscopy (cryo-EM).
- Assessment of neutralization and viral load reduction in vitro and in vivo.
Main Results:
- A panel of human mAbs targeting MeV H and F proteins was generated.
- Nine major epitope clusters were identified across H (four clusters) and F (five clusters).
- Selected mAbs demonstrated potent in vitro virus neutralization and significant in vivo reduction of viral loads, with one mAb achieving undetectable levels.
- High-resolution cryo-EM revealed the structural basis of protective antibody binding to MeV surface proteins.
Conclusions:
- The identified human mAbs provide a detailed map of MeV antibody recognition sites.
- These mAbs exhibit strong neutralizing activity and protective effects in vivo, highlighting their therapeutic potential.
- The findings offer new avenues for prophylactic or therapeutic interventions against measles virus.
More Related Videos
Related Concept Videos
Cross-reactivity
Humoral Immune Responses
Vaccinations
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...

